Bittium Faros 360 Captures 3,199 Ventricular Pauses in Tachy-Brady Syndrome Patient
A 72-year-old male patient presenting with recurrent dizziness and syncope was diagnosed with tachy-brady syndrome after a 14-day continuous EKG monitor recorded 3,199 ventricular pauses, with the longest reaching 6.6 seconds, Cureus reported. The findings revealed persistent atrial fibrillation combined with advanced atrioventricular conduction disease, prompting an emergency admission and successful permanent pacemaker implantation.
Extended EKG Monitoring Detects Silent Arrhythmia Burden
The patient, who carried a medical history of atrial fibrillation, hypertension, and hyperlipidemia, underwent ambulatory monitoring using the Bittium Faros™ 360 Holter recorder. The device successfully captured over 13 days of analyzable data, revealing an average heart rate of 66 beats per minute alongside thousands of unheralded pauses. Medical personnel noted that the longest 6.6-second pause occurred without any reported symptoms from the patient.
Conventional grading for first-, second-, or third-degree atrioventricular block proved inapplicable during the periods of persistent atrial fibrillation due to the absence of organized atrial activity. High-grade atrioventricular conduction disease was confirmed on the cardiac tracings, distinguishing the clinical picture from a simple sinus pause or standard heart block.
Emergency Pacemaker Implantation Prevents Further Syncopal Events
Because the individual was already maintained on oral anticoagulation therapy with apixaban alongside antihypertensive medications including metoprolol and valsartan, clinicians evaluated potential medication-induced orthostatic effects before confirming the primary arrhythmic etiology. Upon identifying the severe pauses, medical teams initiated an urgent referral for device therapy. The patient underwent emergency permanent pacemaker implantation during the hospital admission. Post-procedure evaluations confirmed that the patient maintained his regimen of apixaban and blood pressure medications while reporting a complete resolution of syncopal episodes during follow-up evaluations.
Wearable Technology Advances Arrhythmia Detection
Broader medical research into continuous bio-sensing technology highlights the growing role of automated heart-rate monitoring in capturing life-threatening rhythm disorders. A prospective study published on PMC examined the CardiacSense wrist-worn photoplethysmography device on eighteen patients undergoing induced arrhythmias, demonstrating a high correlation coefficient of R = 0.949 when compared against simultaneous standard electrocardiographic gold-standard recordings. That study successfully tested the watch-like sensor against provoked transient ventricular asystole, monomorphic ventricular tachycardia, and ventricular fibrillation in a controlled setting.
While photoplethysmography-based wearable monitors have seen widespread clinical application for detecting outpatient atrial fibrillation, evaluating their efficacy in capturing rapid, life-threatening ventricular events represents an ongoing area of investigation. Continuous surveillance tools remain critical for identifying intermittent electrical failures that standard short-duration office EKG recordings frequently miss.
Worth a look